Share on StockTwits

FBR Capital Markets began coverage on shares of NPS Pharmaceuticals (NASDAQ:NPSP) in a research note issued on Thursday. The firm set an “outperform” rating on the stock.

NPS Pharmaceuticals (NASDAQ:NPSP) traded up 0.11% during mid-day trading on Thursday, hitting $27.17. 1,404,308 shares of the company’s stock traded hands. NPS Pharmaceuticals has a 52-week low of $21.60 and a 52-week high of $39.68. The stock has a 50-day moving average of $29.79 and a 200-day moving average of $30.74. The company has a market cap of $2.895 billion and a price-to-earnings ratio of 1357.00.

NPS Pharmaceuticals (NASDAQ:NPSP) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $56.10 million for the quarter, compared to the consensus estimate of $53.06 million. During the same quarter in the previous year, the company posted ($0.13) earnings per share. The company’s revenue for the quarter was up 53.7% on a year-over-year basis. Analysts expect that NPS Pharmaceuticals will post $0.02 EPS for the current fiscal year.

NPSP has been the subject of a number of other recent research reports. Analysts at Jefferies Group reiterated a “hold” rating on shares of NPS Pharmaceuticals in a research note on Thursday, August 7th. They now have a $26.00 price target on the stock, up previously from $25.00. Analysts at Janney Montgomery Scott initiated coverage on shares of NPS Pharmaceuticals in a research note on Thursday, May 22nd. They set a “buy” rating and a $37.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. NPS Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $39.85.

NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.